NewYork Presbyterian is purchasing three more WasteLog® systems as part of an expanded Drug Diversion Prevention Program. After installation and upgrade, NewYork Presbyterian will have a total of 8 WasteLog® systems.
The NewYork Presbyterian (NYP), one of the US's most prestigious hospital chains with 10 hospitals in the bouroughs of New York, chose in April 2019 to purchase a total of 5 DrugLog® units for its facilities in New York. The systems have been used to check that returned narcotic drugs have not been replaced or tampered with and are part of NYP's overall program to prevent Drug Diversion. NYP has now chosen to acquire three WasteLog® systems and will simultaneously convert existing DrugLog® systems to WasteLog®. WasteLog® has a specially developed software and offers a customized workflow and has functionality specifically intended for so-called Waste Screening. The agreement is with Pharmacolog Inc. and has an approximate order value of SEK 1.3 million.
CEO, Mats Högberg comments: “We are extremely proud that NYP chooses to expand with three additional units to a total of 8 systems. The deal with NYP that we entered just over two years ago was our breakthrough order in the US and has been of great importance for our expansion in North America. That is why it is very gratifying that they choose to expand with three more systems and convert the first five DrugLog units to WasteLog. Thanks to the fact that our solutions are designed to be maintained and serviced remotely, the team has been able to provide a very high level of service, despite an ongoing pandemic.”
For more information contact:
Mats Högberg, CEO
Email: mats.hogberg@pharmacolog.com
Phone: +46 70-546 50 21
This information is insider information that Pharmacolog AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on June 18, 2021 at 17:15.
About Pharmacolog AB
Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company’s first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog’s long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at http://www.pharmacolog.com. The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.
Release